ICM
BIOL

Invenomic Capital Management’s Biolase, Inc. BIOL Stock Holding History

Invenomic Capital Management’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-243
Closed -$253K – 166
2020
Q4 		$253K Buy
243
+223
+1,115% +$170K 0.06% 121
2020
Q3 		$14K Sell
20
-2
-9% -$1.88K 0.01% 140
2020
Q2 		$26K Buy
+22
New +$25.1K 0.02% 150

Other funds holding BIOL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DA
DCM Advisors New York $220M AUM 23.37% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invenomic Capital Management's BIOL Position: Q1 2021 in Review

Invenomic Capital Management sold out of Biolase, Inc. (BIOL) in Q1 2021, closing a stake of 243 shares — an estimated $253K sold.

Invenomic Capital Management first reported a position in BIOL in Q2 2020 and held it in 3 quarters. The position peaked at $253K in Q4 2020. 32 funds tracked by Wall St. Rank hold BIOL as of Q1 2021.

  • Invenomic Capital Management reported no remaining Biolase, Inc. position as of Q1 2021 after selling out during the quarter.
  • Invenomic Capital Management sold 243 Biolase, Inc. shares in Q1 2021, an estimated $253K.
  • Invenomic Capital Management first reported a position in Biolase, Inc. in Q2 2020 and held it in 3 quarters.
  • Invenomic Capital Management's Biolase, Inc. position peaked at $253K in Q4 2020.
  • 32 funds tracked by Wall St. Rank held Biolase, Inc. as of Q1 2021.

Based on Invenomic Capital Management's 13F filing for Q1 2021, filed 13 May 2021.